RE: ZONA
Assuming ZONA gets a temporary bounce from their stock buyback announcement, I am considering shorting it. Problem is I know very little about the drug industry, except maybe that Percodan kills a headache better than aspirin. So can somebody help me out here by answering one question?
According to Asensio, Vasomax doesn't work, never has, never will, and that's been widely known for years. Yet, in November, Shering-Plough forked over 10 million in cash for rights to market the drug, and promised another 47.5 million subject to FDA approval.
Why didn't Shering-Plough know what Asensio knew or, conversely, what does Shering-Plough know that Asensio doesn't know? (e.g., is the fix already in for FDA approval?, etc.)
Thanks in advance. |
